Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2026)
Avalo Therapeutics (AVTX) recorded EBITDA Margin of -33433.90% in Q4 2025, down 26536.50 percentage points from -6897.40% a year earlier.
Powered by 
Analysis
Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2026) Analysis & Trends
For FY2025, Avalo Therapeutics reported EBITDA Margin of -123018.64%, down 107521.37 percentage points from FY2024.
- Annual EBITDA Margin has declined for three straight years, with a five-year change of -121958.78 percentage points (FY2020 to FY2025).
- Across earlier years, EBITDA Margin came in at -15497.28% in FY2024 (-14083.92 pp), -1413.36% in FY2023 (-1206.86 pp), -206.49% in FY2022 (+1284.37 pp) and -1490.87% in FY2021 (-431.01 pp).
- The Q4 2025 figure is the lowest quarterly EBITDA Margin in data going back to Q3 2016.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 7083.20 percentage points in Q4 2022, against a drop of 26536.50 percentage points in Q4 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.22 Bn | 1,133.81 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 646.28 Bn | 566.14 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 503.17 Bn | 476.28 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 365.23 Bn | 319.60 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 302.66 Bn | 266.65 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 267.39 Bn | 241.08 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 241.61 Bn | 197.01 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 172.91 Bn | 119.55 Bn | 10.94 Bn | 39.16% |
| 10 | Avalo Therapeutics | 325.27 Mn | -366.95 Mn | - | -1,140.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,140.89% |
| Mar 31, 2026 | -2,600.75% |
| Dec 31, 2025 | -33,433.90% |
| Jun 30, 2025 | -1,748.59% |
| Mar 31, 2025 | -1,266.03% |
| Dec 31, 2024 | -6,897.40% |
| Sep 30, 2024 | -5,151.41% |
| Dec 31, 2023 | -1,333.63% |
| Sep 30, 2023 | -1,093.22% |
| Jun 30, 2023 | -1,051.32% |
| Mar 31, 2023 | -1,770.32% |
| Dec 31, 2022 | -945.42% |
| Sep 30, 2022 | 29.99% |
| Jun 30, 2022 | -1,109.58% |
| Mar 31, 2022 | -1,742.20% |
| Dec 31, 2021 | -7,908.22% |
| Sep 30, 2021 | -1,160.52% |
| Jun 30, 2021 | -493.86% |
| Mar 31, 2021 | -6,369.77% |
| Dec 31, 2020 | -1,055.51% |
API Access
Avalo Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=AVTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "AVTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=AVTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();